PriMera Scientific Surgical Research and Practice (ISSN: 2836-0028)

Review Article

Volume 6 Issue 3

Pomegranate: The Savier of Ovarian Cancer

Adsul Samruddhi Subhash* and Wable Madhuri Sanjay*

August 29, 2025

View PDF

Abstract

Ovarian cancer is the fifth most common cause of death for women overall and the leading cause of death for women diagnosed with gynaecological cancers. The majority of cases are diagnosed at an advanced stage, which results in poor outcomes for this disease. The key early detection strategies include transvaginal ultrasound, a laboratory marker such as the cancer antigen-125 assay, and a detailed gynaecological evaluation; however, anti-angio genic bevacizumab and Poly (ADP-ribose) polymerase (PARP) inhibitors have gained traction in the management of this gynaecological malignancy in the last ten years. After the initial treatment, a high rate of recurrence has been noted. The majority of these relapsed cases are known to have a higher rate of treatment failures and are less treatable. Therefore, there is an urgent need for innovative treatment methods based on a deeper understanding of the molecular characteristics of this malignancy as well as efficient preventive and detection strategies. In addition to reviewing the epidemiology and risk factors of ovarian cancer, this article discusses some recent ongoing studies and emphasizes the evaluation and multidisciplinary approach in the care of this condition.

Keywords: Ovarian cancer; Pomegranate; Menopause; Tumor

References

  1. Hong MK and Ding DC. “Early diagnosis of ovarian cancer: A comprehensive review of the advances, challenges, and future directions”. Diagnostics 15.4 (2025): 406.
  2. Liberto JM., et al. “Current and emerging methods for ovarian cancer screening and diagnostics: a comprehensive review”. Cancers 14.12 (2022): 2885
  3. Sahu SA and Shrivastava D. “A comprehensive review of screening methods for ovarian masses: Towards earlier detection”. Cureus 15.11 (2023).
  4. Krankenberg DJ., et al. “Ovarian cancer management in an ESGO ovarian cancer center of excellence: a systematic case study of the interprofessional and interdisciplinary interaction”. Archives of Gynecology and Obstetrics 309.6 (2024): 2821-8.
  5. Webb PM and Jordan SJ. “Global epidemiology of epithelial ovarian cancer”. Nature Reviews Clinical Oncology 21.5 (2024): 389-400.
  6. Schoutrop E., et al. “Molecular, cellular and systemic aspects of epithelial ovarian cancer and its tumor microenvironment”. InSeminars in cancer biology. Academic Press 86 (2022): 207-223.
  7. De Leo A., et al. “What is new on ovarian carcinoma: integrated morphologic and molecular analysis following the new 2020 World Health Organization classification of female genital tumors”. Diagnostics 11.4 (2021): 697.
  8. Huang J., et al. “Worldwide burden, risk factors, and temporal trends of ovarian cancer: a global study”. Cancers 14.9 (2022): 2230.
  9. Ali AT, Al-Ani O and Al-Ani F. “Epidemiology and risk factors for ovarian cancer”. Menopause Review/Przegląd Menopauzalny 22.2 (2023): 93-104.
  10. Vaiphei SD. “Understanding End-of-Life Care: Psychological Approaches to Cancer Care”. Taylor & Francis (2025).
  11. La Marca A and Diamanti M. “Factors affecting age at menopause and their relationship with ovarian reserve: A comprehensive review”. The European Journal of Contraception & Reproductive Health Care 29.5 (2024): 245-55.
  12. Bertozzi S., et al. “Breast cancer care for the aging population: a focus on age-related disparities in breast cancer treatment”. BMC cancer 25.1 (2025): 492.
  13. Mantovani G., et al. “Primary or Interval Debulking Surgery for Advanced Endometrial Cancer with Carcinosis: A Systematic Review and Individual Patient Data Meta-Analysis of Survival Outcomes”. Cancers 17.6 (2025): 1026.
  14. Wang ZB., et al. “Ovarian cancer targeted medication: PARP inhibitors, anti-angiogenic drugs, immunotherapy, and more, volume II”. Frontiers in Pharmacology 16 (2025): 1552652
  15. Tsolakidis D., et al. “Evaluating the Impact of Hyperthermic Intraperitoneal Chemotherapy (HIPEC) on Interval and Secondary Debulking in Ovarian Cancer: A Systematic Review”. Cancers 17.5 (2025): 904.
  16. Webb PM and Jordan SJ. “Global epidemiology of epithelial ovarian cancer”. Nature Reviews Clinical Oncology 21.5 (2024): 389-400.
  17. Fu Z, Taylor S and Modugno F. “Lifetime ovulations and epithelial ovarian cancer risk and survival: a systematic review and meta-analysis”. Gynecologic oncology 165.3 (2022): 650-63.
  18. Didziokaite G., et al. “Oxidative stress as a potential underlying cause of minimal and mild endometriosis-related infertility”. International Journal of Molecular Sciences 24.4 (2023): 3809.
  19. Barili V., et al. “Genetic basis of breast and ovarian cancer: approaches and lessons learnt from three decades of inherited predisposition Testing”. Genes 15.2 (2024): 219.
  20. Palleschi M. Exploring the role of rare germline variants in non-coding regions of cancer predisposition genes in triple-negative breast cancer patients (2024).
  21. Otsuka I. “Mechanisms of high-grade serous carcinogenesis in the fallopian tube and ovary: current hypotheses, etiologic factors, and molecular alterations”. International journal of molecular sciences 22.9 (2021): 4409.
  22. Li Y., et al. “Global, regional, and National burden of breast, cervical, uterine, and ovarian cancer and their risk factors among women from 1990 to 2021, and projections to 2050: findings from the global burden of disease study 2021”. BMC cancer 25.1 (2025): 330.
  23. Rees A., et al. “Screening Methods to Discover the FDA-Approved Cancer Drug Encorafenib as Optimally Selective for Metallothionein Gene Loss Ovarian Cancer”. Genes 16.1 (2025): 42.
  24. Shen Y., et al. “Molecular characteristics of early-and late-onset ovarian cancer: insights from multidimensional evidence”. Journal of Ovarian Research 18.1 (2025): 83.
  25. Wei YF., et al. “Worldwide patterns and trends in ovarian cancer incidence by histological subtype: a population-based analysis from 1988 to 2017”. EClinicalMedicine (2025).
  26. Mongiovi JM., et al. “Associations between parity, history of breastfeeding, and T cell profile of ovarian tumors”. Cancer Epidemiology, Biomarkers & Prevention (2025).
  27. Zhang J, Wang M and Wu Y. “Risk Factors for Recurrence in Serous Borderline Ovarian Tumors and Early-Stage Low-Grade Serous Ovarian Carcinoma”. Current Oncology 32.5 (2025): 263.
  28. Haddadi R. Managing the Unseen: A Qualitative Study on Polycystic Ovary Syndrome-Related Pain and Symptom Management (Master's thesis, University of Twente).
  29. Yan M and Yuan Z. “Chloroplast Genome of Pomegranate. In The Pomegranate Genome”. CRC Press (2025): 70-75.
  30. Huang Z, Foo SC and Choo WS. “A review on the extraction of polyphenols from pomegranate peel for punicalagin purification: techniques, applications, and future prospects”. Sustainable Food Technology (2025).
  31. Martínez-Méndez DD., et al. “Ballota hirsuta Benth Arrests the Cell Cycle, Induces Apoptosis and Inhibits the Invasion of MCF-7 and MDA-MB-231 Cell Lines in 2D and 3D Models”. International Journal of Molecular Sciences 26.12 (2025): 5672.
  32. Al Hoque A, Begum S and Dutta D. “Occurrence, Chemical Nature, and Medicinal Benefits of Flavonoids-Rutin, Kaempferol, Quercetin, Anthocyanidins, Catechins, and Flavones”. In Dietary Supplements and Nutraceuticals. Singapore: Springer Nature Singapore (2025): 1-24.
  33. Rauf A., et al. “Ferulic acid as a promising candidate for developing selective and effective anti-cancer therapies”. Discover Oncology 16 (2025): 1214.
  34. . Manmuan S., et al. “Phytochemical analysis, antioxidant activity, and cytotoxic effects of Caulerpa lentillifera extracts inducing cell apoptosis and sub-G/G0-G1 cell cycle arrest in KON oral cancer cells”. BMC Complementary Medicine and Therapies 25.1 (2025): 101.
  35. Namwan N., et al. “Synergistic Anti-Cancer Activities of Curcumin Derivative CU17 Combined with Gemcitabine Against A549 Non-Small-Cell Lung Cancer Cells”. Pharmaceutics 17.2 (2025): 158.
  36. Ashaolu TJ., et al. “Extraction and stabilization of pomegranate seed oil: a functional oil for the food industry”. Journal of Food Measurement and Characterization 19.1 (2025): 167-84.
  37. D'costa M., et al. “CDK regulators—Cell cycle progression or apoptosis—Scenarios in normal cells and cancerous cells”. Advances in Protein Chemistry and Structural Biology 135 (2023): 125-77.
  38. Palani B., et al. “Bioactive Compounds for Inhibiting Mutated Gene (BRCA1 and BRCA2) Signaling Pathway in Ovarian Cancer Treatment”. Biomedical Materials & Devices (2025): 1-20.
  39. Nunes AR., et al. “Phenolic Acids from Fruit By-Products as Therapeutic Agents for Metabolic Syndrome: A Review”. International Journal of Molecular Sciences 26.8 (2025): 3834.
  40. Mustafa YF. “Role of fruit-derived antioxidants in fighting cancer: a narrative review”. Indian Journal of Clinical Biochemistry (2025): 1-8.
  41. Nguyen TL., et al. “Innovative extraction technologies of bioactive compounds from plant by-products for textile colorants and antimicrobial agents”. Biomass conversion and biorefinery 20 (2024): 24973-5002.
  42. Xu C., et al. “The role of macrophage polarization in ovarian cancer: From molecular mechanism to therapeutic potentials”. Frontiers in Immunology 16 (2025): 1543096.
  43. Bayramoglu EE and Civi S. “Review of tannins currently used in the leather industry”. Part 1: hydrolysable tannins. ICAMS 2024 (2024): 30.
  44. Molnar M., et al. “A comprehensive analysis of diversity, structure, biosynthesis and extraction of biologically active tannins from various plant-based materials using deep eutectic solvents”. Molecules 29.11 (2024): 2615.
  45. Islam MR., et al. “The role of natural and semi-synthetic compounds in ovarian cancer: Updates on mechanisms of action, current trends and perspectives”. Molecules 28.5 (2023): 2070.
  46. Semeradtova A., et al. “Extracellular vesicles in cancer´ s communication: messages we can read and how to answer”. Molecular Cancer 24.1 (2025): 86.
  47. Amer A and Shahin A. “In Vitro Production of Flavonoids”. Plant Specialized Metabolites: Phytochemistry, Ecology and Biotechnology (2025): 1-49.
  48. Masyita A., et al. “Natural pigments: innovative extraction technologies and their potential application in health and food industries”. Frontiers in Pharmacology 15 (2025): 1507108.
  49. Lazić AM., et al. “Harnessing the potential of selected plant pigments in dye-sensitized solar cells: the current status”. Hemijska industrija 79.1 (2025): 47-65.
  50. An J., et al. “Organic Functional Groups and Their Substitution Sites in Natural Flavonoids: A Review on Their Contributions to Antioxidant, Anti‐Inflammatory, and Analgesic Capabilities”. Food Science & Nutrition 13.5 (2025): e70191.
  51. Schwarzlmueller P., et al. “Steroid hormones as modulators of anti-tumoural immunity”. Nature Reviews Endocrinology (2025): 1-3.